Keyword: Alder Biopharmaceuticals
A few days after leaving Insmed to take up an “employment opportunity on the West Coast”, Paul Streck has popped up at migraine specialist Alder.
Teva is ending a phase 3 trial of its CGRP blocker in chronic cluster headache after an analysis showed it was unlikely to meet its primary endpoint.
Alder hires Juno exec as CEO, Allergan brings in Abbott vet after investors demand change, and ResTORbio poaches Novartis researcher as clinical VP.
Alder BioPharmaceuticals poached Juno’s COO to lead the company, as it preps to submit its migraine treatment for FDA approval and heavy competition.
The oral CGRP drug ubrogepant met its endpoints in a second phase 3 migraine trial, setting it up for an NDA in 2019.
Alder says data showing its IV drug eptinezumab can extend pain-free days between migraines makes it an important treatment option.
The decision, which Alder described as mutual, leaves the biotech without a permanent leader in the runup to filing for approval of its migraine drug.
The stock sale will set Alder up to forge ahead with development of a migraine drug it thinks can compete with rivals such as Amgen and Eli Lilly.
Eli Lilly has posted positive data from three phase 3 trials of galcanezumab in migraine patients.
Amgen and Novartis have cleared one of the final hurdles in the tight race to bring a CGRP migraine drug to market.